Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF FEBRUARY 01, 2026 SAM #8833
SOLICITATION NOTICE

65 -- Notice of Intent - Nucleic acid�based reagents for in vivo transient protein expression

Notice Date

1/30/2026 7:43:09 AM
 

Notice Type

Presolicitation
 

NAICS

325413 — In-Vitro Diagnostic Substance Manufacturing
 

Contracting Office

PROGRAM SUPPORT CENTER ACQ MGMT SVC ROCKVILLE MD 20857 USA
 

ZIP Code

20857
 

Solicitation Number

NIH-26-006363-IntentNotice
 

Response Due

2/14/2026 10:00:00 AM
 

Archive Date

03/01/2026
 

Point of Contact

Ivan Mora-Juarez, Phone: 3014430055
 

E-Mail Address

ivan.mora-juarez@hhs.gov
(ivan.mora-juarez@hhs.gov)
 

Small Business Set-Aside

NONE No Set aside used
 

Description

This notice is not a request for competitivequotations or capability statements. The intent of this notice is for informational purposes only. Please do not call or submit questions/inquiries via email, concerning this presolicitation notice update. ------------------------------------------------------------------------------------------------------------------------ The intent is to award a contract on a solesource basis instead of competititon for Nucleic acid�based reagents for in vivo transient protein expression forthe National Cancer Institute and Center for Cancer Research. The supplies required are nucleic acid-based reagents. The proposed work focuses on the use of nucleic acid-based reagents to investigate preventive strategies against viral infection of HIV/Simian Immunodeficiency virus (SIV) and HTLV in preclinical models. The proposed studies will utilize nucleic-acid based reagents that express viral antigens as a preventive treatment to be tested in appropriate models. Nucleic acid-based reagents have been used in prior preclinical studies, conducted by the AMRVS, as preventive countermeasures against viral infections, demonstrating the ability to induce protective immune responses in relevant experimental models. Previous work has shown that such reagents can be designed to express viral antigens that are safe and confer protection against the target pathogen. Collectively, these findings support further preclinical studies as preventive strategies. The requested reagents will provide broader activity against related viral subtypes and other cancer-inducing viruses. It is important to use the same supplier for these reagents in order to ensure consistency with materials used in previous preclinical studies. These reagents can vary in formulation, synthesis methods and purity, and such differences may introduce variability that complicates interpretation of experimental results. Using reagents from the same suppliers enables direct comparison with previously generated data, support reproducibility and ensure continuity in experimental design and data analysis.
 

Web Link

SAM.gov Permalink
(https://sam.gov/workspace/contract/opp/e3675be32c5f47f3801816ac68017a33/view)
 

Place of Performance

Address: Philadelphia, PA 19104, USA

Zip Code: 19104

Country: USA
 

Record

SN07702368-F 20260201/260130230040 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |